These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27881503)

  • 1. The Preventive-Pill Paradox: How Shared Decision Making Could Increase Cardiovascular Morbidity and Mortality.
    Diprose W; Verster F
    Circulation; 2016 Nov; 134(21):1599-1600. PubMed ID: 27881503
    [No Abstract]   [Full Text] [Related]  

  • 2. Coronary Artery Calcium and Shared Decision Making.
    Hecht HS; Shaw LJ; Chandrashekhar Y; Narula J
    JACC Cardiovasc Imaging; 2016 May; 9(5):637-9. PubMed ID: 27151526
    [No Abstract]   [Full Text] [Related]  

  • 3. Statins.
    Ratchford EV; Martin SS
    Vasc Med; 2017 Oct; 22(5):442-445. PubMed ID: 28803537
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey.
    Burstein B; Altobelli KK; Williams K; Cannon CP; Pencina MJ; Sniderman AD; Thanassoulis G
    Circulation; 2017 Nov; 136(19):1860-1862. PubMed ID: 29109198
    [No Abstract]   [Full Text] [Related]  

  • 5. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association.
    Wiggins BS; Saseen JJ; Page RL; Reed BN; Sneed K; Kostis JB; Lanfear D; Virani S; Morris PB;
    Circulation; 2016 Nov; 134(21):e468-e495. PubMed ID: 27754879
    [No Abstract]   [Full Text] [Related]  

  • 6. High-Quality Statin Trials Support the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines After the HOPE-3 Trial (Heart Outcomes Prevention Evaluation-3): MESA (The Multiethnic Study of Atherosclerosis).
    Mortensen MB; Budoff M; Li D; Nasir K; Blaha MJ; Sandfort V; Jose Rodriguez C; Ouyang P; Falk E
    Circulation; 2017 Nov; 136(19):1863-1865. PubMed ID: 28634218
    [No Abstract]   [Full Text] [Related]  

  • 7. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I; Smith G
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract]   [Full Text] [Related]  

  • 8. Nonadherence to statins: individualized intervention strategies outside the pill box.
    Lansberg P; Lee A; Lee ZV; Subramaniam K; Setia S
    Vasc Health Risk Manag; 2018; 14():91-102. PubMed ID: 29872306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin Intolerance From a Clinician's Perspective.
    Whayne TF
    Angiology; 2016 Mar; 67(3):205-7. PubMed ID: 26019266
    [No Abstract]   [Full Text] [Related]  

  • 10. Questioning the benefits of statins.
    Mazowita G
    CMAJ; 2005 Nov; 173(10):1210; author reply 1210. PubMed ID: 16275979
    [No Abstract]   [Full Text] [Related]  

  • 11. What to say and how to say it: effective communication for cardiovascular disease prevention.
    Navar AM; Stone NJ; Martin SS
    Curr Opin Cardiol; 2016 Sep; 31(5):537-44. PubMed ID: 27428113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal screening and drug treatment of dyslipidemia in children and adolescents.
    Psaty BM; Rivara FP
    JAMA; 2012 Jan; 307(3):257-8. PubMed ID: 22174386
    [No Abstract]   [Full Text] [Related]  

  • 13. MY APPROACH to the Patient With Memory Loss Who Needs a Statin.
    Watson KE; Sallam T
    Trends Cardiovasc Med; 2017 Feb; 27(2):158-159. PubMed ID: 28107839
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular risk profile and use of statins at the age of 70 years: a comparison of two Finnish birth cohorts born 20 years apart.
    Upmeier E; Vire J; Korhonen MJ; Isoaho H; Lehtonen A; Arve S; Wuorela M; Viitanen M
    Age Ageing; 2016 Jan; 45(1):84-90. PubMed ID: 26764397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Communicating statin evidence to support shared decision-making.
    Barrett B; Ricco J; Wallace M; Kiefer D; Rakel D
    BMC Fam Pract; 2016 Apr; 17():41. PubMed ID: 27048421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinician Decision Support Tools: Advances in Lipid-Lowering Treatment Intensification.
    Marvel FA; Grant JK; Martin SS
    Circ Cardiovasc Qual Outcomes; 2024 May; 17(5):e010884. PubMed ID: 38634283
    [No Abstract]   [Full Text] [Related]  

  • 17. Many organisations support shared decision making.
    Leng G
    BMJ; 2017 Jan; 356():j479. PubMed ID: 28130243
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of the impact of the recent controversy over statins in France: the EVANS study.
    Saib A; Sabbah L; Perdrix L; Blanchard D; Danchin N; Puymirat E
    Arch Cardiovasc Dis; 2013 Oct; 106(10):511-6. PubMed ID: 24080324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplifying the approach to the management of dyslipidemia.
    Gaziano JM; Gaziano TA
    JAMA; 2009 Nov; 302(19):2148-9. PubMed ID: 19920241
    [No Abstract]   [Full Text] [Related]  

  • 20. Questioning the benefits of statins.
    Vos E; Rose CP
    CMAJ; 2005 Nov; 173(10):1207; author reply 1210. PubMed ID: 16275976
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.